Chorea is a common motor symptom of Huntington Disease (HD) which impacts motor function. Valbenazine, a potent and selective vesicular monoamine transporter 2 inhibitor, is being investigated for the treatment of chorea associated HD, and was approved for the treatment of tardive dyskinesia in the United States in 2017. Prof. Erin Furr-Stimming (McGovern Medical School, University of Texas, Health Science Centre, Houston, TX, USA) joins touchNEUROLOGY to discuss the KINECT-HD phase 3 trial, which evaluated the efficacy, safety, and tolerability of valbenazine for the treatment of chorea associated with HD.
Watch part 1 of this interview, where Prof. Erin Furr-Stimming also discusses the current treatment landscape for Huntington disease.
The abstracted entitled: ‘KINECT HD: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Valbenazine for Chorea Associated with Huntington Disease (HD)‘ was presented at the American Academy of Neurology (AAN) annual meeting, April 2-7, 2022.
Questions:
1. What were the aims, design and eligibility criteria of the KINECT-HD study? (0:23)
2. What were the efficacy outcome measures of the study and how well were they achieved? (1:15)
3. What were the safety findings, and what was the impact of valbenazine on suicidal ideation in the study population? (3:39)
Disclosures: Erin Furr-Stimming receives indirect grant/research support from HSG provided by NBI to UTHealth for her role as principal investigator on the Kinect-HD study, and no direct grant/research support remuneration from UniQure, CHDI, HDSA, Cures within Reach, Prilennia, and Roche/Genetech.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
